Our goal at Advaxis is to fundamentally alter the way physicians and patients think about cancer by utilizing advances in genomic and molecular analysis, combined with our unique Lm Technology™, to create immunotherapies that specifically target cancer without affecting normal tissue. Our treatments enable the body to recognize tumors as threats that should be targeted by the body’s natural defenses.
Every individual is naturally equipped to battle cancer. One of the jobs of the immune system is to seek out and kill cells that have mutated and developed the ability to become cancerous. However, sometimes the cells gain mutations that allow them to avoid the immune system, and the cancer then gains a foothold and can grow unchecked. Advaxis’ core technology platform uses bioengineered Listeria monocytogenes (Lm) bacteria to stimulate the immune system to view tumor cells as bacterial infected cells and target them for elimination.
Advaxis is headquartered in Princeton, New Jersey and was founded in 2002. The company was incorporated in Delaware in 2006. In 2016, Advaxis unveiled their new state-of-the-art manufacturing and laboratory facility onsite at their Princeton headquarters. Since its inception, Advaxis has focused its development efforts on understanding its platform technology and establishing a drug development pipeline that incorporates the company’s Lm Technology™ into therapeutic cancer immunotherapies. The company has partnered with leading academic centers and biopharmaceutical industry leaders on the development of its immunotherapy candidates and looks to expand its candidates alone and in combination with potentially synergistic technologies.